graft-versus-host disease after allogeneic hematopoietic stem cell
Conditions
Interventions
FMT
Sponsors
Shiga University of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Presence or absence of primary therapy and steroid-resistant or steroid-dependent presence do not matter. (2) Age is one younger than 65 years 20 years old or older. (3) Performance status (PS) is 0, 1, 2 patients. (4) About participation in this study, as for the person. It can be a provider (donor) an agreement is obtained from one, following. (1) It is a person within the third degree from a study participant (recipients) (2) It is a person until 65 years old 20 years old or older (3) The one that can have you offer feces 200 g or more on the day of transplantation
Exclusion criteria
Exclusion criteria: (1) A blood test: HIV, HTLV-1, syphilis, liver dysfunction, hepatitis A, hepatitis B, hepatitis C, cytomegalovirus, EB virus, amoebic dysentery (2) A feces examination: Helicobacter pylori, Yersinia, Campylobactor, dysentery, Salmonella, hemorrhagic enteropathic E.coli, rotavirus, adenovirus, norovirus, parasitic worm screening, ova of parasites screening, Clostridium difficile (CD toxin A/B)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A utility eight weeks after FMT for GVHD after allogeneic hematopoietic stem cell transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| A safety eight weeks after FMT for GVHD after allogeneic hematopoietic stem cell transplantation. | — |
Countries
Japan
Contacts
Public ContactHirotsugu Imaeda
Shiga University of Medical Science Division of Gastroenterology, Department of Medicine
Outcome results
None listed